Principal Investigator
Eugene Schiff
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20210795
Clinical Trial Summary
A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis
Phase
Phase III
Funding Agency/Sponsor
Industry
Disease
NASH and fibrosis (stages 1-3)
Contact Information
Study Contact
Sonia Carvalho
Phone Number
+1 (305) 2434639
Email
scarvalho@miami.edu